Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

NAVIDEA E Form 4 May 05, 2011	310PHARMAC 5	CEUTICAI	LS, INC.								
FORM	4						OMB APPROVAL				
	UNITEL	Was					NGE C	COMMISSION	OMB Number:	3235-0287	
Check thi if no long subject to Section 1 Form 4 or Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pu Section 17	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							January 31 Expires: 2005 Estimated average burden hours per response 0.5		
(Print or Type R	Responses)										
LARSON BRENT L Symbol NAVII BIOPH			Symbol NAVID	'IDEA PHARMACEUTICALS, INC.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director10% Owner			
(Last) 5600 BLAZ 200					of Earliest Transaction /Day/Year)				Director (give title Other (specify below) below) EVP, CFO, Treas and Sec'y		
DUBLIN, O	(Street) 0H US 43017	Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
		(Zin)						Person			
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Da (Month/Day/Yea	r) Execution any		a I - Non-Do 3. Transactio Code (Instr. 8) Code V	4. Securiti	ies Ac sposed	quired of (D)	uired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock	05/01/2015			S <u>(1)</u>	12,500	D	\$ 1.33 (2)	309,737	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
LARSON BRENT L 5600 BLAZER PARKWAY, SUITE 200 DUBLIN, OH US 43017			EVP, CFO, Treas and Sec'y				
Signatures							

William J. Kelly, 05/05/2015 attorney-in-fact

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015

Weighted average of sales prices ranging from \$1.31 to \$1.35 per share. Mr. Larson undertakes to provide upon request by the Staff of the (2) Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.